Kura Oncology (KURA) Financials

$5.90 +0.15 (+2.61%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$5.90 +0.00 (+0.08%)

As of 04/17/2025 04:25 PM Eastern

Annual Income Statements for Kura Oncology

This table shows Kura Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-136	-153	-174
Consolidated Net Income / (Loss)	-136	-153	-174
Net Income / (Loss) Continuing Operations	-136	-153	-174
Total Pre-Tax Income	-136	-153	-172
Total Operating Income	-140	-166	-193
Total Gross Profit	0.00	0.00	54
Total Revenue	0.00	0.00	54
Operating Revenue	0.00	0.00	54
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	140	166	247
Selling, General & Admin Expense	47	51	77
Research & Development Expense	93	115	170
Total Other Income / (Expense), net	4.03	13	21
Interest Expense	0.23	1.55	1.62
Interest & Investment Income	4.25	15	23
Income Tax Expense	0.00	0.00	2.02
Basic Earnings per Share	($2.03)	($2.08)	($2.02)
Weighted Average Basic Shares Outstanding	66.99M	73.23M	86.16M
Diluted Earnings per Share	($2.03)	($2.08)	($2.02)
Weighted Average Diluted Shares Outstanding	66.99M	73.23M	86.16M
Weighted Average Basic & Diluted Shares Outstanding	68.44M	76.14M	80.75M

This table shows Kura Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-36	-33	-34	-37	-37	-44	-50	-50	-53	-21
Consolidated Net Income / (Loss)	-36	-33	-34	-37	-39	-43	-50	-51	-54	-19
Net Income / (Loss) Continuing Operations	-36	-33	-34	-37	-39	-43	-50	-51	-54	-19
Total Pre-Tax Income	-36	-33	-34	-37	-39	-43	-50	-51	-54	-17
Total Operating Income	-37	-35	-37	-40	-42	-47	-54	-56	-60	-22
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	54
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	54
Total Operating Expenses	37	35	37	40	42	47	54	56	60	76
Selling, General & Admin Expense	12	12	11	12	13	14	18	17	18	24
Research & Development Expense	25	23	25	28	29	33	36	40	42	52
Total Other Income / (Expense), net	1.09	2.04	2.50	2.83	3.87	3.98	4.93	5.57	5.48	5.26
Interest Expense	0.00	0.23	0.36	0.39	0.40	0.39	0.40	0.41	0.41	0.40
Interest & Investment Income	1.09	2.27	2.86	3.22	4.28	4.37	5.33	5.97	5.89	5.66
Basic Earnings per Share	($0.53)	($0.49)	($0.50)	($0.53)	($0.50)	($0.55)	($0.59)	($0.59)	($0.63)	($0.21)
Weighted Average Basic Shares Outstanding	66.89M	66.99M	68.40M	69.80M	77.24M	73.23M	83.91M	86.64M	86.95M	86.16M
Diluted Earnings per Share	($0.53)	($0.49)	($0.50)	($0.53)	($0.50)	($0.55)	($0.59)	($0.59)	($0.63)	($0.21)
Weighted Average Diluted Shares Outstanding	66.89M	66.99M	68.40M	69.80M	77.24M	73.23M	83.91M	86.64M	86.95M	86.16M
Weighted Average Basic & Diluted Shares Outstanding	66.90M	68.44M	68.44M	74.24M	74.27M	76.14M	76.18M	76.63M	77.76M	80.75M

This table details how cash moves in and out of Kura Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-39	-14	187
Net Cash From Operating Activities	-110	-125	134
Net Cash From Continuing Operating Activities	-110	-125	134
Net Income / (Loss) Continuing Operations	-136	-153	-174
Consolidated Net Income / (Loss)	-136	-153	-174
Depreciation Expense	0.76	0.85	0.85
Amortization Expense	1.68	-8.94	-13
Non-Cash Adjustments To Reconcile Net Income	27	27	35
Changes in Operating Assets and Liabilities, net	-3.55	8.50	285
Net Cash From Investing Activities	33	16	-102
Net Cash From Continuing Investing Activities	33	16	-102
Purchase of Property, Plant & Equipment	-0.63	-0.17	-0.47
Purchase of Investments	-271	-410	-659
Sale and/or Maturity of Investments	304	426	558
Net Cash From Financing Activities	39	95	154
Net Cash From Continuing Financing Activities	39	95	154
Repayment of Debt	-0.58	0.00	0.00
Issuance of Debt	10	0.00	0.00
Issuance of Common Equity	29	95	154
Cash Interest Paid	0.07	1.06	1.10

This table details how cash moves in and out of Kura Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	52	-39	-25	22	-20	8.58	4.19	3.68	4.30	175
Net Cash From Operating Activities	-21	-27	-36	-26	-29	-34	-49	-43	-43	269
Net Cash From Continuing Operating Activities	-21	-27	-36	-26	-29	-34	-49	-43	-43	269
Net Income / (Loss) Continuing Operations	-36	-33	-34	-37	-39	-43	-50	-51	-54	-19
Consolidated Net Income / (Loss)	-36	-33	-34	-37	-39	-43	-50	-51	-54	-19
Depreciation Expense	0.19	0.21	0.21	0.21	0.22	0.21	0.23	0.20	0.21	0.20
Amortization Expense	0.37	-0.58	-1.57	-1.99	-2.77	-2.61	-3.15	-3.42	-3.30	-2.75
Non-Cash Adjustments To Reconcile Net Income	6.59	7.15	7.02	7.30	7.37	5.70	8.74	8.97	7.82	9.32
Changes in Operating Assets and Liabilities, net	7.35	-0.19	-7.46	6.03	4.76	5.17	-5.15	2.56	6.24	282
Net Cash From Investing Activities	72	-47	11	-46	8.56	42	-95	43	46	-95
Net Cash From Continuing Investing Activities	72	-47	11	-46	8.56	42	-95	43	46	-95
Purchase of Property, Plant & Equipment	-0.38	-0.01	-0.04	-0.10	-0.02	-0.02	-0.08	-0.02	-	-0.37
Purchase of Investments	-57	-106	-74	-140	-97	-100	-195	-162	-62	-241
Sale and/or Maturity of Investments	129	59	85	93	105	142	100	205	107	146
Net Cash From Financing Activities	0.88	35	0.00	94	0.08	0.69	148	3.04	2.20	0.81
Net Cash From Continuing Financing Activities	0.88	35	0.00	94	0.08	0.69	148	3.04	2.20	0.81
Issuance of Common Equity	0.88	25	0.00	94	0.08	0.69	148	3.04	2.20	0.81

This table presents Kura Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	456	449	760
Total Current Assets	446	432	745
Cash & Equivalents	52	37	224
Short-Term Investments	386	387	503
Prepaid Expenses	8.44	8.52	17
Plant, Property, & Equipment, net	2.54	1.86	1.68
Total Noncurrent Assets	7.34	15	14
Other Noncurrent Operating Assets	7.34	15	14
Total Liabilities & Shareholders' Equity	456	449	760
Total Liabilities	36	52	347
Total Current Liabilities	24	35	79
Short-Term Debt	-	0.00	2.61
Accounts Payable	22	34	50
Current Deferred Revenue	-	0.00	24
Other Current Liabilities	2.32	1.51	1.88
Total Noncurrent Liabilities	12	16	268
Long-Term Debt	9.16	9.33	6.92
Noncurrent Deferred Revenue	-	0.00	254
Other Noncurrent Operating Liabilities	2.81	7.07	6.99
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	420	397	414
Total Preferred & Common Equity	420	397	414
Preferred Stock	0.00	0.00	0.00
Total Common Equity	420	397	414
Common Stock	997	1,120	1,308
Retained Earnings	-569	-721	-895
Accumulated Other Comprehensive Income / (Loss)	-8.03	-1.27	0.76

This table presents Kura Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	448	426	495	474	554	515	479
Total Current Assets	436	416	486	460	538	500	463
Cash & Equivalents	91	27	49	29	42	45	49
Short-Term Investments	337	379	428	424	486	446	406
Prepaid Expenses	8.62	11	8.67	7.32	11	8.25	7.89
Plant, Property, & Equipment, net	2.73	2.37	2.25	2.06	1.71	1.52	1.32
Total Noncurrent Assets	8.86	7.16	6.84	12	14	14	14
Other Noncurrent Operating Assets	8.86	7.16	6.84	12	14	14	14
Total Liabilities & Shareholders' Equity	448	426	495	474	554	515	479
Total Liabilities	28	31	35	44	49	49	55
Total Current Liabilities	25	19	24	28	32	33	40
Short-Term Debt	-	-	-	-	-	0.85	1.72
Accounts Payable	22	17	22	26	31	31	37
Other Current Liabilities	2.30	2.33	2.35	1.68	1.36	1.47	1.69
Total Noncurrent Liabilities	3.62	12	11	16	17	16	15
Long-Term Debt	-	9.20	9.24	9.29	9.38	8.58	7.76
Other Noncurrent Operating Liabilities	3.62	2.36	1.92	7.02	7.18	7.02	6.94
Total Equity & Noncontrolling Interests	420	395	460	430	505	466	424
Total Preferred & Common Equity	420	395	460	430	505	466	424
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	420	395	460	430	505	466	424
Common Stock	965	1,004	1,105	1,112	1,277	1,288	1,299
Retained Earnings	-536	-603	-640	-679	-771	-822	-876
Accumulated Other Comprehensive Income / (Loss)	-9.42	-5.90	-5.22	-3.54	-0.82	-0.46	1.12

This table displays calculated financial ratios and metrics derived from Kura Oncology's official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-9.14%	-26.54%	-17.87%
EBIT Growth	-6.56%	-18.55%	-16.52%
NOPAT Growth	-6.56%	-18.55%	-16.52%
Net Income Growth	-4.12%	-12.36%	-13.99%
EPS Growth	-3.05%	-2.46%	2.88%
Operating Cash Flow Growth	-5.27%	-13.41%	207.61%
Free Cash Flow Firm Growth	-5.24%	-6.51%	241.38%
Invested Capital Growth	24.69%	-102.97%	-1,653.30%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-3.21%	-8.51%	10.55%
EBIT Q/Q Growth	-1.54%	-7.53%	11.18%
NOPAT Q/Q Growth	-1.54%	-7.53%	11.18%
Net Income Q/Q Growth	-0.27%	-6.77%	11.93%
EPS Q/Q Growth	0.49%	-2.97%	14.41%
Operating Cash Flow Q/Q Growth	-2.96%	-6.65%	179.42%
Free Cash Flow Firm Q/Q Growth	-2.81%	-4.41%	205.63%
Invested Capital Q/Q Growth	-4.84%	-29.81%	-1,279.49%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	100.00%
EBITDA Margin	0.00%	0.00%	-380.39%
Operating Margin	0.00%	0.00%	-358.55%
EBIT Margin	0.00%	0.00%	-358.55%
Profit (Net Income) Margin	0.00%	0.00%	-322.89%
Tax Burden Percent	100.00%	100.00%	101.17%
Interest Burden Percent	97.12%	92.06%	89.01%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-29.31%	-37.34%	-42.91%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	-31.96%
Return on Assets (ROA)	0.00%	0.00%	-28.78%
Return on Common Equity (ROCE)	-29.31%	-37.34%	-42.91%
Return on Equity Simple (ROE_SIMPLE)	-32.32%	-38.42%	-42.06%
Net Operating Profit after Tax (NOPAT)	-98	-116	-135
NOPAT Margin	0.00%	0.00%	-250.98%
Net Nonoperating Expense Percent (NNEP)	-8.01%	-8.67%	-6.84%
Return On Investment Capital (ROIC_SIMPLE)	-22.80%	-28.54%	-31.96%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	143.11%
R&D to Revenue	0.00%	0.00%	315.44%
Operating Expenses to Revenue	0.00%	0.00%	458.55%
Earnings before Interest and Taxes (EBIT)	-140	-166	-193
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-137	-174	-205
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.98	2.69	1.64
Price to Tangible Book Value (P/TBV)	1.98	2.69	1.64
Price to Revenue (P/Rev)	0.00	0.00	12.57
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.02	0.02	0.02
Long-Term Debt to Equity	0.02	0.02	0.02
Financial Leverage	-1.02	-1.03	-1.40
Leverage Ratio	1.07	1.11	1.49
Compound Leverage Factor	1.04	1.02	1.33
Debt to Total Capital	2.13%	2.30%	2.25%
Short-Term Debt to Total Capital	0.00%	0.00%	0.62%
Long-Term Debt to Total Capital	2.13%	2.30%	1.63%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.87%	97.70%	97.75%
Debt to EBITDA	-0.07	-0.05	-0.05
Net Debt to EBITDA	3.12	2.38	3.50
Long-Term Debt to EBITDA	-0.07	-0.05	-0.03
Debt to NOPAT	-0.09	-0.08	-0.07
Net Debt to NOPAT	4.38	3.57	5.31
Long-Term Debt to NOPAT	-0.09	-0.08	-0.05
Altman Z-Score	12.18	10.00	-0.19
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	18.56	12.26	9.46
Quick Ratio	18.21	12.02	9.24
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-101	-107	152
Operating Cash Flow to CapEx	-17,581.79%	-74,300.00%	28,456.99%
Free Cash Flow to Firm to Interest Expense	-439.77	-69.24	93.66
Operating Cash Flow to Interest Expense	-480.62	-80.58	82.96
Operating Cash Flow Less CapEx to Interest Expense	-483.35	-80.69	82.67
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.09
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	30.43
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-8.55	-17	-304
Invested Capital Turnover	0.00	0.00	-0.34
Increase / (Decrease) in Invested Capital	2.80	-8.80	-287
Enterprise Value (EV)	401	653	-41
Market Capitalization	830	1,068	677
Book Value per Share	$6.28	$5.35	$5.32
Tangible Book Value per Share	$6.28	$5.35	$5.32
Total Capital	429	407	423
Total Debt	9.16	9.33	9.52
Total Long-Term Debt	9.16	9.33	6.92
Net Debt	-429	-415	-718
Capital Expenditures (CapEx)	0.63	0.17	0.47
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-16	-27	-59
Debt-free Net Working Capital (DFNWC)	422	397	669
Net Working Capital (NWC)	422	397	666
Net Nonoperating Expense (NNE)	38	37	39
Net Nonoperating Obligations (NNO)	-429	-415	-718
Total Depreciation and Amortization (D&A)	2.44	-8.09	-12
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-108.89%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	1,241.07%
Net Working Capital to Revenue	0.00%	0.00%	1,236.23%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.03)	($2.08)	($2.02)
Adjusted Weighted Average Basic Shares Outstanding	66.99M	73.23M	86.16M
Adjusted Diluted Earnings per Share	($2.03)	($2.08)	($2.02)
Adjusted Weighted Average Diluted Shares Outstanding	66.99M	73.23M	86.16M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	68.44M	76.14M	80.75M
Normalized Net Operating Profit after Tax (NOPAT)	-98	-116	-135
Normalized NOPAT Margin	0.00%	0.00%	-250.98%
Pre Tax Income Margin	0.00%	0.00%	-319.15%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-610.76	-107.04	-119.33
NOPAT to Interest Expense	-427.53	-74.93	-83.53
EBIT Less CapEx to Interest Expense	-613.50	-107.15	-119.62
NOPAT Less CapEx to Interest Expense	-430.27	-75.04	-83.82
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Kura Oncology's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-11.45%	-13.67%	-20.40%	-21.61%	-24.96%	-38.36%	-51.23%	-42.71%	-39.88%	49.16%
EBIT Growth	-8.66%	-6.41%	-11.54%	-13.22%	-16.07%	-33.01%	-48.91%	-41.00%	-40.99%	51.98%
NOPAT Growth	-8.66%	-6.41%	-11.54%	-13.22%	-16.07%	-33.01%	-48.91%	-41.00%	-40.99%	51.98%
Net Income Growth	-6.41%	-1.13%	-4.98%	-6.92%	-8.73%	-29.21%	-45.37%	-36.75%	-40.94%	55.09%
EPS Growth	-6.00%	2.00%	-2.04%	-1.92%	5.66%	-12.24%	-18.00%	-11.32%	-26.00%	61.82%
Operating Cash Flow Growth	14.57%	-13.54%	-11.47%	15.57%	-38.16%	-29.32%	-36.16%	-66.02%	-49.65%	884.46%
Free Cash Flow Firm Growth	-7.30%	-1.75%	8.54%	37.06%	9.70%	12.70%	3.34%	-52.15%	-35.54%	1,233.13%
Invested Capital Growth	15.84%	24.69%	60.34%	-950.46%	-63.93%	-102.97%	-734.67%	-98.91%	-64.99%	-1,653.30%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-4.88%	1.39%	-6.76%	-10.14%	-7.77%	-9.19%	-16.69%	-3.94%	-5.63%	60.31%
EBIT Q/Q Growth	-3.57%	3.93%	-4.01%	-9.40%	-6.17%	-10.10%	-16.45%	-3.58%	-6.17%	62.50%
NOPAT Q/Q Growth	-3.57%	3.93%	-4.01%	-9.40%	-6.17%	-10.10%	-16.45%	-3.58%	-6.17%	62.50%
Net Income Q/Q Growth	-2.11%	6.73%	-2.88%	-9.11%	-3.84%	-10.84%	-15.75%	-2.65%	-7.02%	64.68%
EPS Q/Q Growth	-1.92%	7.55%	-2.04%	-6.00%	5.66%	-10.00%	-7.27%	0.00%	-6.78%	66.67%
Operating Cash Flow Q/Q Growth	30.75%	-26.27%	-35.21%	28.59%	-13.31%	-18.19%	-42.37%	12.93%	-2.14%	719.55%
Free Cash Flow Firm Q/Q Growth	17.50%	-0.96%	-1.80%	25.77%	-18.38%	2.40%	-12.71%	-16.84%	-5.45%	915.97%
Invested Capital Q/Q Growth	-963.10%	-4.84%	82.26%	-431.11%	-65.91%	-29.81%	27.03%	-26.57%	-37.61%	-1,279.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-46.39%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-41.67%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-41.67%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-35.66%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	111.73%
Interest Burden Percent	97.02%	94.19%	93.17%	92.93%	90.89%	91.50%	90.95%	90.13%	90.85%	76.59%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-28.42%	-29.31%	-31.55%	-30.77%	-33.65%	-37.34%	-37.34%	-39.27%	-46.28%	-42.91%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3.71%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3.18%
Return on Common Equity (ROCE)	-28.42%	-29.31%	-31.55%	-30.77%	-33.65%	-37.34%	-37.34%	-39.27%	-46.28%	-42.91%
Return on Equity Simple (ROE_SIMPLE)	-32.28%	0.00%	-34.78%	-30.43%	-33.25%	0.00%	-33.28%	-39.00%	-46.62%	0.00%
Net Operating Profit after Tax (NOPAT)	-26	-25	-26	-28	-30	-33	-38	-39	-42	-16
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-29.17%
Net Nonoperating Expense Percent (NNEP)	-2.04%	-1.80%	-1.93%	-2.00%	-2.04%	-2.38%	-2.50%	-2.39%	-2.81%	-0.62%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.73%	-	-	-	-8.05%	-	-	-	-3.71%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	44.67%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	97.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	141.67%
Earnings before Interest and Taxes (EBIT)	-37	-35	-37	-40	-42	-47	-54	-56	-60	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-36	-36	-38	-42	-45	-49	-57	-60	-63	-25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.18	1.98	2.12	1.58	1.57	2.69	3.14	3.37	3.53	1.64
Price to Tangible Book Value (P/TBV)	2.18	1.98	2.12	1.58	1.57	2.69	3.14	3.37	3.53	1.64
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	12.57
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Long-Term Debt to Equity	0.00	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Financial Leverage	-1.02	-1.02	-1.01	-1.01	-1.03	-1.03	-1.02	-1.03	-1.04	-1.40
Leverage Ratio	1.06	1.07	1.06	1.06	1.09	1.11	1.09	1.09	1.12	1.49
Compound Leverage Factor	1.03	1.01	0.99	0.99	0.99	1.01	0.99	0.98	1.01	1.14
Debt to Total Capital	0.00%	2.13%	2.28%	1.97%	2.11%	2.30%	1.82%	1.98%	2.19%	2.25%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.18%	0.40%	0.62%
Long-Term Debt to Total Capital	0.00%	2.13%	2.28%	1.97%	2.11%	2.30%	1.82%	1.80%	1.79%	1.63%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	97.87%	97.72%	98.03%	97.89%	97.70%	98.18%	98.02%	97.81%	97.75%
Debt to EBITDA	0.00	-0.07	-0.06	-0.06	-0.06	-0.05	-0.05	-0.04	-0.04	-0.05
Net Debt to EBITDA	0.00	3.12	2.76	3.09	2.77	2.38	2.68	2.28	1.95	3.50
Long-Term Debt to EBITDA	0.00	-0.07	-0.06	-0.06	-0.06	-0.05	-0.05	-0.04	-0.03	-0.03
Debt to NOPAT	0.00	-0.09	-0.09	-0.09	-0.09	-0.08	-0.07	-0.07	-0.06	-0.07
Net Debt to NOPAT	0.00	4.38	3.95	4.51	4.11	3.57	4.03	3.44	2.93	5.31
Long-Term Debt to NOPAT	0.00	-0.09	-0.09	-0.09	-0.09	-0.08	-0.07	-0.06	-0.05	-0.05
Altman Z-Score	18.49	12.94	15.16	11.43	8.06	10.87	18.29	17.68	14.40	0.55
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	17.64	18.56	21.65	20.32	16.71	12.26	16.67	14.94	11.47	9.46
Quick Ratio	17.29	18.21	21.10	19.96	16.44	12.02	16.34	14.69	11.28	9.24
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-27	-27	-28	-21	-25	-24	-27	-32	-33	271
Operating Cash Flow to CapEx	-5,514.44%	-221,083.33%	-99,644.44%	-26,684.38%	-145,135.00%	-214,425.00%	-58,147.62%	-265,812.50%	0.00%	72,347.04%
Free Cash Flow to Firm to Interest Expense	0.00	-119.70	-76.66	-53.52	-60.69	-60.74	-67.77	-77.62	-80.66	672.86
Operating Cash Flow to Interest Expense	0.00	-115.85	-98.55	-66.19	-71.85	-87.08	-122.72	-104.75	-105.44	667.82
Operating Cash Flow Less CapEx to Interest Expense	0.00	-115.90	-98.65	-66.44	-71.90	-87.12	-122.93	-104.79	-105.44	666.90
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.09
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	30.43
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-8.15	-8.55	-1.52	-8.06	-13	-17	-13	-16	-22	-304
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.34
Increase / (Decrease) in Invested Capital	1.54	2.80	2.31	-7.29	-5.21	-8.80	-11	-7.97	-8.69	-287
Enterprise Value (EV)	486	401	440	256	234	653	1,066	1,086	1,052	-41
Market Capitalization	914	830	837	724	677	1,068	1,584	1,569	1,497	677
Book Value per Share	$6.27	$6.28	$5.77	$6.72	$5.79	$5.35	$6.02	$6.12	$5.53	$5.32
Tangible Book Value per Share	$6.27	$6.28	$5.77	$6.72	$5.79	$5.35	$6.02	$6.12	$5.53	$5.32
Total Capital	420	429	404	469	439	407	514	475	433	423
Total Debt	0.00	9.16	9.20	9.24	9.29	9.33	9.38	9.42	9.47	9.52
Total Long-Term Debt	0.00	9.16	9.20	9.24	9.29	9.33	9.38	8.58	7.76	6.92
Net Debt	-428	-429	-397	-468	-443	-415	-518	-482	-446	-718
Capital Expenditures (CapEx)	0.38	0.01	0.04	0.10	0.02	0.02	0.08	0.02	0.00	0.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-16	-16	-8.68	-15	-20	-27	-22	-24	-31	-59
Debt-free Net Working Capital (DFNWC)	412	422	397	462	432	397	506	467	425	669
Net Working Capital (NWC)	412	422	397	462	432	397	506	466	423	666
Net Nonoperating Expense (NNE)	9.89	8.50	8.47	9.17	8.87	10	11	11	12	3.50
Net Nonoperating Obligations (NNO)	-428	-429	-397	-468	-443	-415	-518	-482	-446	-718
Total Depreciation and Amortization (D&A)	0.56	-0.38	-1.37	-1.78	-2.55	-2.40	-2.91	-3.22	-3.10	-2.54
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-108.89%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,241.07%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,236.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.53)	($0.49)	($0.50)	($0.53)	($0.50)	($0.55)	($0.59)	($0.59)	($0.63)	($0.21)
Adjusted Weighted Average Basic Shares Outstanding	66.89M	66.99M	68.40M	69.80M	77.24M	73.23M	83.91M	86.64M	86.95M	86.16M
Adjusted Diluted Earnings per Share	($0.53)	($0.49)	($0.50)	($0.53)	($0.50)	($0.55)	($0.59)	($0.59)	($0.63)	($0.21)
Adjusted Weighted Average Diluted Shares Outstanding	66.89M	66.99M	68.40M	69.80M	77.24M	73.23M	83.91M	86.64M	86.95M	86.16M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	66.90M	68.44M	68.44M	74.24M	74.27M	76.14M	76.18M	76.63M	77.76M	80.75M
Normalized Net Operating Profit after Tax (NOPAT)	-26	-25	-26	-28	-30	-33	-38	-39	-42	-16
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-29.17%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-31.92%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-153.52	-100.46	-103.37	-105.13	-118.69	-136.81	-138.93	-145.35	-55.72
NOPAT to Interest Expense	0.00	-107.46	-70.32	-72.36	-73.59	-83.08	-95.77	-97.25	-101.74	-39.00
EBIT Less CapEx to Interest Expense	0.00	-153.57	-100.55	-103.62	-105.18	-118.73	-137.03	-138.97	-145.35	-56.64
NOPAT Less CapEx to Interest Expense	0.00	-107.52	-70.42	-72.60	-73.64	-83.12	-95.98	-97.29	-101.74	-39.93
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Kura Oncology's Financials

When does Kura Oncology's fiscal year end?

According to the most recent income statement we have on file, Kura Oncology's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Kura Oncology's net income changed over the last 2 years?

Kura Oncology's net income appears to be on an upward trend, with a most recent value of -$173.98 million in 2024, rising from -$135.84 million in 2022. The previous period was -$152.63 million in 2023.

What is Kura Oncology's operating income?

Kura Oncology's total operating income in 2024 was -$193.20 million, based on the following breakdown:

Total Gross Profit: $53.88 million
Total Operating Expenses: $247.08 million

How has Kura Oncology revenue changed over the last 2 years?

Over the last 2 years, Kura Oncology's total revenue changed from $0.00 in 2022 to $53.88 million in 2024, a change of 5,388,300,000.0%.

How much debt does Kura Oncology have?

Kura Oncology's total liabilities were at $346.52 million at the end of 2024, a 570.7% increase from 2023, and a 861.8% increase since 2022.

How much cash does Kura Oncology have?

In the past 2 years, Kura Oncology's cash and equivalents has ranged from $37.32 million in 2023 to $224.46 million in 2024, and is currently $224.46 million as of their latest financial filing in 2024.

How has Kura Oncology's book value per share changed over the last 2 years?

Over the last 2 years, Kura Oncology's book value per share changed from 6.28 in 2022 to 5.32 in 2024, a change of -15.3%.

Related Companies

This page (NASDAQ:KURA) was last updated on 4/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Financials

Frequently Asked Questions About Kura Oncology's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Financials

Annual Income Statements for Kura Oncology

Quarterly Income Statements for Kura Oncology

Annual Cash Flow Statements for Kura Oncology

Quarterly Cash Flow Statements for Kura Oncology

Annual Balance Sheets for Kura Oncology

Quarterly Balance Sheets for Kura Oncology

Annual Metrics and Ratios for Kura Oncology

Quarterly Metrics and Ratios for Kura Oncology

Frequently Asked Questions About Kura Oncology's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools